

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6996)

RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board hereby announces with effect from December 16, 2021:

- (1) Mr. Yanling Cao has resigned from his office as a non-executive Director; and
- (2) Mr. Yilun Liu has been appointed as a non-executive Director.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of Antengene Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Yanling Cao (“**Mr. Cao**”) has resigned from his office as a non-executive Director with effect from December 16, 2021 in order to devote more time to other work commitments. After resignation, Mr. Cao no longer holds any position in the Group.

Mr. Cao has confirmed (i) he has no disagreement with the Board; and (ii) there are no matters with respect to his resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or the shareholders of the Company.

The Board expresses its appreciation to Mr. Cao for his contributions to the Board during his tenure of services with the Company.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

In addition, the Board is pleased to announce that Mr. Yilun Liu (“**Mr. Liu**”) has been appointed as a non-executive Director with effect from December 16, 2021.

The biographical details of Mr. Liu are set out below:

Mr. Yilun Liu, aged 35, has been a director of Keymed Biosciences Inc., a company whose shares are listed on the Main Board of the Stock Exchange (Stock Code: 2162), since March 3, 2021, and was re-designated as a non-executive director on April 3, 2021. He participates in decision-making in respect of major matters of Keymed Biosciences Inc. such as corporate and business strategies. Mr. Liu has experience working in the financial industry, including serving as the head of special situation at Anatole Investment Management Limited (晨曦投資管理有限公司). Since April 2018, Mr. Liu has been an executive director at Boyu Capital Group Management Ltd.. Mr. Liu received his Bachelor of Science degree in marketing from Fudan University (復旦大學) in the People's Republic of China in July 2009. He then obtained his master of business administration degree from Columbia Business School in May 2015.

Mr. Liu entered into a service contract with the Company which the initial term of his service contract shall be three years commencing on December 16, 2021 until terminated in accordance with the terms and conditions of the service contract or by either party giving to the other not less than one month's prior notice. Mr. Liu will receive no remuneration as director's fee.

Save as disclosed above, Mr. Liu does not hold any other position with the Group, has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years prior to the date of his appointment and does not have other major appointments and professional qualifications.

Save as disclosed above, to the best knowledge of the Company, Mr. Liu does not have any relationship with any other director, senior management, substantial shareholder or controlling shareholder of the Company, and does not have any interests in the shares in the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) as at the date of this announcement.

Save as disclosed above, there is no other information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange, nor are there any other matters, relating to the appointment of Mr. Liu that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Liu in joining the Company.

By Order of the Board
Antengene Corporation Limited.
Dr. Jay Mei
Chairman

Hong Kong, December 16, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Dr. Kevin Patrick Lynch and Mr. Donald Andrew Lung as executive directors; Mr. Yanling Cao and Dr. Kan Chen as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.